Pharmaceuticals

WIT DYNE

WIT DYNE released FY2025 Annual Earnings on April 23 (BJT), actual revenue CNY 2.228 B (forecast CNY 2.32 B), actual EPS CNY 2.28 (forecast CNY 2.38)

WIT DYNE released FY2025 Q4 earnings on April 23 (BJT), actual revenue CNY 625.79 M, actual EPS CNY 0.5387

WIT DYNE released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 412.27 M, actual EPS CNY 0.47

WIT DYNE FY2026 Q1 Earnings Release on April 24 After-Market BJT

WIT DYNE to Release FY2025 Annual Earnings on April 24, 2026 (BJT), Forecast Revenue CNY 2.32 B, EPS CNY 2.38

WIT DYNE released FY2025 9 Months Earnings on October 24 After-Market (BJT), Actual Revenue CNY 1.603 B, Actual EPS CNY 1.7416

WIT DYNE released FY2025 Q3 earnings on October 24 After-Market BJT, actual revenue CNY 432.12 M, actual EPS CNY 0.3013

WIT DYNE to Release FY2025 Q3 Earnings on October 25 After-Market (BJT)

WIT DYNE released FY2025 Semi-Annual Earnings on August 7 After-Market (BJT), Actual Revenue: CNY 1.17 B, Actual EPS: CNY 1.44

WIT DYNE released FY2025 Q2 earnings on August 7 After-Market (BJT), actual revenue CNY 554.19 M, actual EPS CNY 0.6602

WIT DYNE to Release FY2025 Semi-Annual Earnings on August 8, 2025 (BJT)

Huate Dain Secretary Responds to Investors on Dividend, Repurchase Plans, and Share Purchasing

Investor Asks Huatide 关于 Children's Lead Poisoning Medication

Guo Weisong 增持 Huatai Dayin 股份 3.7%

Guo Weisong Increases Holdings in Huatideyin by 1%

Huate Dain Secretary Responds to Investors on Innovative Drug R&D

Guo Weisong Raises Stake in Huate Daining to Threshold

Guo Weisong Increases Stake in Huatai Dain to 5%

Dayin Pharmaceutical Receives Approval for Clinical Trials of Ipratropium Bromide Inhalation Aerosol

Huatai Dainuo's Subsidiary Dainuo Pharmaceutical Receives Registration Certificate for Valproic Acid Oral Solution

000915

According to the Zhitong Finance APP, WIT DYNE released its Q3 2025 report. In the first three quarters, the company achieved operating revenue of 1.603 billion yuan, a year-on-year increase of 16.30%. The net profit attributable to shareholders of the listed company was 408 million yuan, a year-on-year increase of 11.67%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 400 million yuan, a year-on-year increase of 15.80%

Zhitong

WIT DYNE released its performance for the first three quarters, with a net profit attributable to the parent company of 408 million yuan, a year-on-year increase of 11.67%

WIT DYNE announced that its revenue for the third quarter was 432 million yuan, a year-on-year increase of 93.28%; net profit was 70.5981 million yuan, a year-on-year increase of 110.42%. Revenue for the first three quarters was 1.603 billion yuan, a year-on-year increase of 16.30%; net profit was 408 million yuan, a year-on-year increase of 11.67%

WIT DYNE: The net profit for the third quarter was 70.5981 million yuan, a year-on-year increase of 110.42%

WIT DYNE announced that the interim dividend for 2025 will be based on a total share capital of 234 million shares as of June 30, 2025, distributing a cash dividend of 5 yuan for every 10 shares to all shareholders of the company, without increasing share capital from capital reserves or issuing bonus shares. The actual cash dividend amount for the first half of 2025 will be 117 million yuan. The equity registration date is October 16, 2025, and the ex-dividend date is October 17, 2025

WIT DYNE: A cash dividend of 5 yuan for every 10 shares

WIT DYNE released its semi-annual report for 2025, with operating revenue of 1.17 billion yuan, a year-on-year increase of 1.39%; net profit attributable to shareholders of 337 million yuan, a year-on-year increase of 1.69%. The net profit after deducting non-recurring gains and losses was 332 million yuan, a year-on-year increase of 4.31%. The basic earnings per share were 1.44 yuan, and it plans to distribute a cash dividend of 5 yuan (including tax) for every 10 shares to all shareholders

WIT DYNE released its performance for the first half of the year, with a net profit attributable to the parent company of 337 million yuan, an increase of 1.69%

WIT DYNE's subsidiary Beijing Dainkangjian Pharmaceutical Co., Ltd. has signed an exclusive general distribution agreement for melatonin granules (Manlejing®) with Japan's NOBORI Pharmaceutical Co., Ltd. According to the agreement, Dainkangjian will become the exclusive general distributor of the product in mainland China, responsible for the import, marketing, and sales of the product

WIT DYNE subsidiary signs general distribution contract for melatonin granules (Manlejing)

WIT DYNE announced that major shareholder Guo Weisong, holding more than 5% of shares, increased his holdings by a total of 8.66 million shares from June 30, 2025, to July 1, 2025, accounting for 3.7% of the company's total share capital. After this increase, Mr. Guo Weisong holds a total of 22.72 million shares in the company, representing 9.7% of the company's total share capital

WIT DYNE: Shareholder Guo Weisong increased his stake in the company to 3.7%

688382

688513

300016

The chemical pharmaceutical sector experienced a surge, with ST Tian Sheng hitting the limit up, followed by WIT DYNE, InventisBio, *ST Suwu, EASTON BIOPHARMACEUTICALS, Beilu Pharma, and others rising

InventisBio

EASTON BIOPHARMACEUTICALS

Beilu Pharma

The chemical pharmaceutical sector experiences a surge, with ST Tian Sheng hitting the daily limit

WIT DYNE shareholder Guo Weisong plans to increase his holdings of the company's shares by 4.33 million to 8.66 million shares through the Shenzhen Stock Exchange within 6 months starting from June 26, 2025, accounting for approximately 1.85% to 3.70% of the total share capital

WIT DYNE shareholder Guo Weisong plans to increase his holdings from 4.33 million shares to 8.66 million shares

WIT DYNE announced on the evening of June 18 that on June 17, Guo Weisong increased his holdings in WIT DYNE by 24,400 shares through the centralized bidding system of the Shenzhen Stock Exchange, bringing his total holdings to 11,716,600 shares, with a shareholding ratio of 5%. Guo Weisong does not rule out the possibility of continuing to increase his equity stake in the company within the next 12 months. This change in equity will not lead to a change in the company's controlling shareholder and actual controller

WIT DYNE: Received a stake from Guo Weisong, with shareholding ratio reaching 5%

According to the Zhitong Finance APP, WIT DYNE announced that its subsidiary, Dain Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial application of the isopropyl bromide inhalation aerosol. This drug is intended for the prevention and treatment of respiratory difficulties associated with chronic obstructive airway diseases in children and adults; chronic obstructive bronchitis with or without emphysema; and the treatment of mild to moderate bronchial asthma

WIT DYNE: Clinical trial application for ipratropium bromide inhalation aerosol drug approved

WIT DYNE(000915.SZ)